- News from the prostate cancer community of interest to you. Last updated May 31, 2019
Us TOO 25th Anniversary
Six members of the Quad Cities chapter attended the anniversary symposium. Valuable information from the symposium can be found in videos of this event at Click here
Latest Treatment Strategies
A recap of some of the most relevant and recent articles about prostate cancer are available from Us Too.
The monthly newsletter, Us TOO HotSheet , highlights the latest in treatment strategies. The features these topics:
The June Hotsheet covers:
- Packing a PUNCH in Prostate Cancer Chemo, ADT & Surgery
- Gleason 8 PCa Diagnosed at Biopsy Frequently Downgraded
- ‘Trexit’ – a Clean Break from Trans-Rectal Prostate Biopsies
- Clinical Utility of CTC Androgen Splice Variant-7 Status
- High-Fat, Diet-Induced Prostate Cancer Development
- Doc Moyad’s No Bogus Science: “Breakfast is Not Important?!”
- Clinical Validation of IsoPSA™
- Prostate Cancer Metastases at Diagnosis on the Rise
- Active Surveillance in Black Men with Low-Risk Prostate Cancer
- Sipuleucel-T Could Be More Widely Used for Advanced Prostate Cancer
- ‘Fake News’ in Urology
- Doctor Chodak’s Bottom Line
- New Entry in ‘Burgeoning Field’ of Prostate Cancer Therapy
NEWS YOU CAN USE ARTICLES:
Us TOO Prostate Cancer NEWS You Can Use from Us TOO
Latest articles of all facets of Prostate Cancer such as Medicare coverage, FDA approvals, new treatments, clinical trials, and studies from around the world can be found at http://www.ustoo.org/Find-News-You-C
- Prostatectomy Beats Active Surveillance Long Term – or Does It?
- Is No Surgery Feasible in Gleason 9 and 10 PCa?
- Prostate Cancer Risk Lower in Long-Term Users of Lipid-Lowering Drugs
- YouTube Videos Often Mislead on Prostate Cancer
- Doc Moyad’s No Bogus Science: “Are Fish Oil Results a Little Fishy?!”
- ADT May Be Less Beneficial for Gleason Score 9 to 10 Prostate Cancer
- Doctor Chodak’s Bottom Line
- Index of Articles Published in the 2018 Hot SHEET
Consequences of a Decline in PSA Testing
A study found that the rate of intermediate- and high-risk prostate cancer are rising among men in the U.S. Current research is examining the impact of a decline in PSA testing in the period after the U.S. Preventative Services Task Force discouraged the use of PSA testing to screen for prostate cancer. See the article the Winter 2015 Quest Newsletter.
Did PSA Test’s Decline Spur Rise in Prostate Cancers?
TUESDAY, Feb. 24, 2015 (HealthDay News) — U.S. recommendations against the PSA test for prostate cancer might have prompted a small but measurable increase in the number of higher-risk cases diagnosed recently, according to a new study. Click here to read article.
Raising Awareness about MRI Imaging of the Prostate
Prostate cancer screening presents a unique challenge. Prostate cancer is a very common, but only a minority of cases are deadly. This creates a serious problem. It’s good to detect high-grade disease because early treatment reduces mortality. But PSA screening detects a lot of men with low-grade disease and these men are harmed. Why? Well-intentioned but over-enthusiastic doctors recommend treatment even though it’s truly medically unnecessary. So what can be done? Physician propensity for overtreatment will only change slowly. The shortest pathway out of this dilemma is to stop diagnosing so much low-grade disease. Click here is read more.
Stop Random Biopsies
Editor’s Note: The new imaging technology discussed in this article is available locally in the Quad Cities through Metro MRI. If you are facing multiple needle biopsies, discuss with your urologist.
MARINA DEL REY, Calif., Sept. 17, 2014 /PRNewswire/ — Prostate Oncology Specialists announces the launch of the Prostate Vanguard, an awareness campaign to educate men about new imaging technology destined to replace multiple rectal needle biopsies of the prostate. Annually, a million men undergo random needle biopsy of the prostate gland through the rectum. Multi-parametric MRI (MP-MRI) of the prostate gland is non-invasive alternative for diagnosing clinically-significant prostate cancer (CSPC). Men need to be fully informed of their alternatives.
Random needle biopsy is a multibillion dollar industry performed in one-million men annually. Random biopsy is the direct cause of the unfortunate diagnosis of clinically insignificant prostate cancer (CIS-PC) in over 100,000 men annually in the US, leading to rampant overuse of unnecessary radical treatment with surgery or radiation.
Mark Scholz, MD, Medical Director of Prostate Oncology Specialists, Executive Director of the Prostate Cancer Research Institute, and author of Invasion of the Prostate Snatchers, devotes his medical practice exclusively to prostate cancer patients and advocates for raising awareness about the importance of unnecessary biopsies.
Dr. Scholz states, “With new imaging technology, the medical world has the ability to track, measure, and observe small abnormalities in the prostate, which saves men from having to undergo random biopsies which lead to misdiagnosis and overtreatment.” Click here for more details.
Women play key role in prostate cancer awareness
Women play a valuable role in reminding the men in their lives to get screened for prostate cancer.
According to the Prostate Cancer Foundation, 1 in 6 men are affected by prostate cancer in the U.S. This makes it the most common cancer in America after skin cancer. This year, an estimated 238,000 men will be diagnosed with the disease – many with almost no symptoms – and more than 30,000 men will lose their lives to it.
If detected early, the cure rate for prostate cancer is almost 100 percent. This means that most men who are diagnosed at an early stage will be disease-free after 5 years. These shocking statistics reiterate the importance of getting screened and staying one step ahead of this “silent killer.” Additionally, men should know they are not alone; more than 2.5 million men are living with prostate cancer in America. Fortunately, there are many viable treatment options available.
Watch this informative video with steps you can take to detect prostate cancer early. Click here.
Us TOO offers cancer journey insights, experiences
By Laura Anderson Shaw
|Photo: Paul Collettiemail@example.com Bill Palos, center, of Coal Valley, is a prostate cancer survivor who helped establish the Greater Quad Cities Us TOO Prostate Cancer Support Group. Volunteers Dave and Donna Evans, also of Coal Valley, have been active members of the group since Dave’s diagnosis in June 2006, and continue to help lead and organize the Us TOO monthly meetings.|
COAL VALLEY — Because of his family history, Dave Evans wasn’t completely caught off guard when he was diagnosed with prostate cancer in June 2006. He was, however, surprised to find a wealth of information and support through the members of the Greater Quad Cities Us TOO Prostate Cancer Support Group. “The group helped me understand all the options, the possible side effects,” the Coal Valley man said. (Click here to see complete story appearing June 16, 2014 on Quad-Cities Online, Dispatch Argus,)
Additional articles of interest
The Prostate Health Index (PHI) test is now available at Northwestern Memorial Hospital in Chicago, offering patients a new option for detecting prostate cancer. In February, WGN News highlighted the PHI test and interviewed urologist Dr. William Catalona in a story entitled “New test means new way to fight prostate cancer.” Watch the WGN feature story here.